Ryohei Yamamoto1,2,3, Takafumi Ito4, Yasuyuki Nagasawa5, Kosuke Matsui6, Masahiro Egawa4, Masayoshi Nanami5, Yoshitaka Isaka7, Hirokazu Okada8. 1. Health and Counseling Center, Osaka University, 1-17 Machikaneyama-cho, Toyonaka, Osaka, 560-0043, Japan. yamamoto@hacc.osaka-u.ac.jp. 2. Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan. yamamoto@hacc.osaka-u.ac.jp. 3. Health Promotion and Regulation, Department of Health Promotion Medicine, Osaka University Graduate School of Medicine, Toyonaka, Japan. yamamoto@hacc.osaka-u.ac.jp. 4. Division of Nephrology, Faculty of Medicine, Shimane University, Izumo, Japan. 5. Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. 6. Department of Nephrology, Izumo Citizens Hospital, Izumo, Japan. 7. Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan. 8. Department of Nephrology, Saitama Medical University, Iruma-gun, Saitama, Japan.
Abstract
BACKGROUND: Several randomized controlled trials (RCTs) have demonstrated the cardiometabolic effects of aerobic exercise in the general population and in patients with cardiovascular diseases. However, the efficacy of aerobic exercise in patients with chronic kidney disease (CKD) remains to be elucidated. METHODS: RCTs comparing aerobic exercise with no aerobic exercise in patients with CKD not requiring kidney replacement therapy were identified through PubMed using RobotAnalyst, a web-based software system that combines text-mining and machine learning algorithms for organizing references. Cardiometabolic and renal outcomes of interest included body mass index (BMI); systolic blood pressure (SBP); hemoglobin A1c (HbA1c), total cholesterol (TCHO), low- and high- density lipoprotein cholesterol (LDLC and HDLC, respectively), and urinary protein (UP) levels/concentration; peak oxygen uptake (Vo2peak); and glomerular filtration rate (GFR) at the end of the follow-up period. The standardized mean difference (SMD) of each outcome was estimated using the DerSimonian-Laird random-effect model with inverse-variance weighting. RESULTS: A total of 15 trials, including 622 patients, were included. Their follow-up periods were 3-4, 6-12, and > 12-months in 7 (46.7%), 7 (46.7%), and 1 (6.7%) trial(s), respectively. Meta-analyses showed that aerobic exercise significantly decreased BMI (SMD, -0.19 [95% confidence interval, -0.38, -0.00]) and SBP (-0.75 [-1.24, -0.26]) and increased Vo2peak (0.54 [0.29, 0.78]); however, no significant association was observed in HbA1c, TCHO, HDLC, LDLC, GFR, and UP. Meta-regression models suggested that aerobic exercise was more likely to improve Vo2peak in patients with younger age, no diabetes, and lower BMI. CONCLUSION: Aerobic exercise of 3-12 months' duration improved obesity, high blood pressure, and low exercise capacity in overweight/obese patients with CKD, but it had no significant effect on GFR and proteinuria. Well-designed large RCTs with a longer follow-up period are needed to evaluate the efficacy of aerobic exercise in patients with CKD.
BACKGROUND: Several randomized controlled trials (RCTs) have demonstrated the cardiometabolic effects of aerobic exercise in the general population and in patients with cardiovascular diseases. However, the efficacy of aerobic exercise in patients with chronic kidney disease (CKD) remains to be elucidated. METHODS: RCTs comparing aerobic exercise with no aerobic exercise in patients with CKD not requiring kidney replacement therapy were identified through PubMed using RobotAnalyst, a web-based software system that combines text-mining and machine learning algorithms for organizing references. Cardiometabolic and renal outcomes of interest included body mass index (BMI); systolic blood pressure (SBP); hemoglobin A1c (HbA1c), total cholesterol (TCHO), low- and high- density lipoprotein cholesterol (LDLC and HDLC, respectively), and urinary protein (UP) levels/concentration; peak oxygen uptake (Vo2peak); and glomerular filtration rate (GFR) at the end of the follow-up period. The standardized mean difference (SMD) of each outcome was estimated using the DerSimonian-Laird random-effect model with inverse-variance weighting. RESULTS: A total of 15 trials, including 622 patients, were included. Their follow-up periods were 3-4, 6-12, and > 12-months in 7 (46.7%), 7 (46.7%), and 1 (6.7%) trial(s), respectively. Meta-analyses showed that aerobic exercise significantly decreased BMI (SMD, -0.19 [95% confidence interval, -0.38, -0.00]) and SBP (-0.75 [-1.24, -0.26]) and increased Vo2peak (0.54 [0.29, 0.78]); however, no significant association was observed in HbA1c, TCHO, HDLC, LDLC, GFR, and UP. Meta-regression models suggested that aerobic exercise was more likely to improve Vo2peak in patients with younger age, no diabetes, and lower BMI. CONCLUSION: Aerobic exercise of 3-12 months' duration improved obesity, high blood pressure, and low exercise capacity in overweight/obese patients with CKD, but it had no significant effect on GFR and proteinuria. Well-designed large RCTs with a longer follow-up period are needed to evaluate the efficacy of aerobic exercise in patients with CKD.
Authors: Marcello Tonelli; Scott W Klarenbach; Anita M Lloyd; Matthew T James; Aminu K Bello; Braden J Manns; Brenda R Hemmelgarn Journal: Kidney Int Date: 2011-08-17 Impact factor: 10.612
Authors: Adrian Thorogood; Salvatore Mottillo; Avi Shimony; Kristian B Filion; Lawrence Joseph; Jacques Genest; Louise Pilote; Paul Poirier; Ernesto L Schiffrin; Mark J Eisenberg Journal: Am J Med Date: 2011-08 Impact factor: 4.965
Authors: Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Jackson Wright; Larry Appel; Tom Greene; Adeera Levin; Ognjenka Djurdjev; David C Wheeler; Martin J Landray; John N Townend; Jonathan Emberson; Laura E Clark; Alison Macleod; Angharad Marks; Tariq Ali; Nicholas Fluck; Gordon Prescott; David H Smith; Jessica R Weinstein; Eric S Johnson; Micah L Thorp; Jack F Wetzels; P J Blankestijn; A D van Zuilen; Vandana Menon; Mark Sarnak; Gerald Beck; Florian Kronenberg; Barbara Kollerits; Marc Froissart; Benedicte Stengel; Marie Metzger; Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; H J Lambers Heerspink; Barry Brenner; Dick de Zeeuw; Peter Rossing; Hans-Henrik Parving; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Alex R Chang; Morgan E Grams; Shoshana H Ballew; Henk Bilo; Adolfo Correa; Marie Evans; Orlando M Gutierrez; Farhad Hosseinpanah; Kunitoshi Iseki; Timothy Kenealy; Barbara Klein; Florian Kronenberg; Brian J Lee; Yuanying Li; Katsuyuki Miura; Sankar D Navaneethan; Paul J Roderick; Jose M Valdivielso; Frank L J Visseren; Luxia Zhang; Ron T Gansevoort; Stein I Hallan; Andrew S Levey; Kunihiro Matsushita; Varda Shalev; Mark Woodward Journal: BMJ Date: 2019-01-10
Authors: Stein I Hallan; Kunihiro Matsushita; Yingying Sang; Bakhtawar K Mahmoodi; Corri Black; Areef Ishani; Nanne Kleefstra; David Naimark; Paul Roderick; Marcello Tonelli; Jack F M Wetzels; Brad C Astor; Ron T Gansevoort; Adeera Levin; Chi-Pang Wen; Josef Coresh Journal: JAMA Date: 2012-12-12 Impact factor: 56.272
Authors: Nathalie Van Aerde; Philippe Meersseman; Yves Debaveye; Alexander Wilmer; Michael P Casaer; Jan Gunst; Joost Wauters; Pieter J Wouters; Kaatje Goetschalckx; Rik Gosselink; Greet Van den Berghe; Greet Hermans Journal: Intensive Care Med Date: 2021-11-08 Impact factor: 17.440